Introduction

IJO

International Journal of Oncology

1019-6439 1791-2423

D.A. Spandidos

10.3892/ijo.2022.5388

IJO-61-02-05388

Review

Molecular targets of primary cilia defects in cancer

Yin

Fengying

Wei

Zihao

Chen

Fangman

Xin

Chuan

Chen

Qianming

Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Zhejiang Provincial Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Research of Zhejiang Province, Cancer Center of Zhejiang University, Hangzhou, Zhejiang 310006, P.R. China

Correspondence to: Professor Qianming Chen, Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Zhejiang Provincial Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Research of Zhejiang Province, Cancer Center of Zhejiang University, 166 QiuTaoBei Road, Hangzhou, Zhejiang 310006, P.R. China, E-mail: qmchen@zju.edu.cn

08 2022

04 07 2022

61 2

30032022 20062022

2022

Primary cilia are hair-like organelles that are present on the majority of mammalian cells. They are regarded as the regulatory ‘hub’ of cell functions due to their indispensable roles for several signaling pathways, such as Hh and Wnt pathways. Originally, cilia defects were found to cause a panoply of human diseases commonly referred to as ‘ciliopathies’. Evidence is accumulating that cilia defects are involved in the onset and development of cancer. Some proteins that cause cilia defects have been identified as oncogenes in multiple cancer types. Hence, understanding the pathways that cause cilia defects in cancer is of utmost importance for the development of novel cancer therapeutic targets. The present review article provides a critical overview of the molecular targets of primary cilia defects in cancer, and highlights their vast potential as therapeutic targets and novel biomarkers.

primary cilia cancer biomarker molecular target

Key Research and Development Program of Zhejiang Province

2021C03074

Fundamental Research Funds for the Central Universities

K20220177

The present study was supported by the Key Research and Development Program of Zhejiang Province (grant no. 2021C03074) and the Fundamental Research Funds for the Central Universities (grant no. K20220177).

1. Introduction

Cilia are evolutionally conserved cell structures protruding from the cell surface, which are found ubiquitously across species from ancient protozoa to humans. They are usually divided into two categories: Motile cilia and primary cilia, both of which consist of the axoneme, matrix and ciliary membrane (Fig. 1). Unlike motile cilia, primary cilia usually lack the dynein motor proteins that power axonemal beating and are therefore immotile (1). For almost 100 years, cilia were considered as anomalous structures without any function, until they were found to be associated with the onset of multiple syndromes, such as Bardet-Biedl (2), Joubert (3), oral-facial-digital (OFD) (4), and Ellis-van Creveld syndrome (5).

There is abundant evidence to indicate that primary cilia tightly regulate numerous critical signaling pathways, such as the Hh, Wnt and Notch signaling pathways. Therefore, primary cilia are regarded as the regulatory ‘hub’ of cell functions (6,7). It is worth noting that, apart from basal cell carcinoma (BCC) (8) and medulloblastoma (9), in which tumorigenesis is cilia-dependent, cilia formation is compromised in multiple tumor types, including melanoma (10), pancreatic cancer (11), breast cancer (12), cholangiocarcinoma (CCA) (13), prostate cancer (14), renal cell carcinoma (RCC) (15) and oral squamous cell carcinoma (OSCC) (16). Since hundreds of proteins and numerous critical signaling pathways are regulated by primary cilia, their proper formation is critical for the integrity of signal transduction and various cellular processes (17). Therefore, molecules that cause primary cilia defects may provide novel approaches with which to attenuate tumor progression, which is the focus of the present review.

2. Primary cilia and the cell cycle

Uncontrolled cell proliferation and deregulation of the cell cycle are hallmarks of malignant tumor formation (18). This section mainly provides a description of the mechanisms through which ciliogenesis is closely associated with the cell cycle.

<sec> <title>Cilia assembly and cell cycle

Ciliogenesis is an elaborately regulated process that begins when cells exit the mitotic cycle (Fig. 2). Ciliogenesis occurs through two main routes: The classic intracellular pathway, in which the short axoneme extends from the basal body before the latter reaches the cytoplasmic membrane (19); and the alternative pathway, in which the axoneme extends from the basal body only after the latter is anchored to the cytoplasmic membrane (20). In fibroblasts, cilia are assembled through the intracellular pathway. When the cell exits the cell cycle, cytoplasmic vesicles are anchored to the distal appendage of the mother centriole and then trigger the remodeling of the mother centriole into the basal body, which is the earliest ciliogenesis event that can be detected (21). The basal body-vesicle complex then migrates to the cell surface and is anchored to the plasma membrane. Under the transport of intraflagellar transport (IFT) complexes, proteins accumulate into cilia through the ‘ciliary gate’, and cilia gradually bulge from the cell surface. Conversely, in polarized epithelial and multiciliated cells, ciliogenesis occurs through the alternative pathway. The basal body localizes at the center of the apical membrane and interacts directly with the membrane, with cilia assembly occurring entirely in the plasma membrane [further details on the ciliogenic pathways observed have been previously described (22)].

Cilia disassembly and cell cycle

In contrast to cilia assembly, the mechanisms underlying cilia disassembly in normal or pathological conditions remain largely unknown (23). Following the stimulation of mitogens, the scaffolding protein human enhancer of filamentation 1 (HEF1) activates aurora kinase A (AURKA) in the basal body, which in turn phosphorylates histone deacetylase 6 (HDAC6) (24). Phosphorylated HDAC6 enters the cilia to remove the acetylation modification of axonemal microtubules, thus inducing cilia disassembly. However, the mechansims through which HEF1 is upregulated and recruited to the basal body following mitogen stimulation remain unclear. In addition to HEF1, Trichoplein (25) and Pitchfork (26) have also been proven to be activators of AURKA in the G1 and S phases, respectively.

In addition to HDAC6, kinesin family member (KIF)24 and KIF2a are also implicated in the de-polymerization of axonemal microtubules. The activity of KIF24 is enhanced by never-in-mitosis-A-related kinase 2 (NEK2) during the S and G2 phases (27), and KIF2a is activated by polo-like kinase 1 (PLK1) in the G2 and M phases (28). Notably, the regulatory mechanisms of AURKA, NEK2 and PLK1 involved in cilia disassembly are relatively conservative and in chronological order, ensuring the irreversibility of cilia resorption following cell cycle entry.

Since the centriole dually functions as the microtubule-organizing center during mitosis and as the basal body for ciliogenesis, a common hypothesis is that cilia anchor the centriole to the cell membrane, thereby depriving the cell of cycle entry (23). The abnormal presence of cilia has been shown to lead to cell cycle arrest observed in in vivo and in vitro models. Trichoplein or AURKA knockdown induce cilia to fail to disassemble, thus inducing G0/G1 arrest. More notably, this phenotype was reversed when cilia formation was prevented by the simultaneous knockdown of IFT20 (25). In a previous study, NudE neurodevelopment protein 1, localizing on the mother centriole, was found to be highly expressed during mitosis and then rapidly degraded when the cell became quiescent. Its silencing in zebrafish and cultured cells led to a significant increase in ciliary length and S phase arrest (29). In addition, in another study, Tctex1 deletion, mainly localizing on the transition zone and regulating ciliary resorption, was shown to resulted in cilia persistence and G1/S phase arrest (30). These studies suggest that cells may sense the presence of primary cilia to limit cell cycle entry; however, further research is required to prove this hypothesis.

Ciliogenesis is a cell cycle-regulated event in normal cells. However, few studies have closely implicated the ciliogenesis changes when the cell cycle is under the influence of malignancies. The most fundamental trait of malignant cells involves their ability to sustain proliferation (31). Therefore, a possible cause of cilia loss in malignant cells could be the increased proliferation. However, Menzl et al (12) found that the loss of primary cilia was not associated with an increased proliferative index (Ki67-positive cells) in breast cancer. Nobutani et al (32) hardly detected primary cilia in cell cycle-arrested human breast cancer cells. Moreover, in a study involving 110 patients with kidney cancer, reduced ciliary ratio was observed to be independent of cell proliferation (15). It is worth noting that ciliogenesis is not restrained in all malignant tumors. The ciliary ratio has been shown to be significantly increased in BCC tissues (33) and cilia have been identified in some subsets of human medulloblastomas which had activation in either Hh or Wnt signaling (9). These studies suggest that cilia defects are characteristic of oncogenic transformation, and this is not only due to the increased proliferation in malignancies.

3. Molecular targets that cause primary cilia defects in cancer

The abnormal expression of certain critical ciliary proteins, which have a number of the hallmarks of oncogenes, can result in severe cilia defects. Although only a few protein inhibitors have been used in clinical practice or in clinical trials (34), targeting these molecules still holds promise for cancer treatment (35). Nevertheless, a number of studies have been primarily observational and do not elaborate on the mechanisms of cancer containment by targeting these ciliary molecules. This section provides a summary and discussion of the mechanisms through which these molecules can cause cilia defects in cancer (Fig. 3).

Molecules regulating cilia assembly Cell cycle-related kinase (CCRK)

CCRK plays a critical role in promoting G1 phase entry and is of interest as it is the closest vertebrate homolog to the long flagella 2, a critical protein controlling the length of flagella in chlamydomonas (36). CCRK localizes in the cytoplasm and tunes ciliary length and shape by coordinating the assembly of the ciliary axoneme and membrane (37,38). In addition, cell cycle regulation by CCRK has been found to be dependent on primary cilia. The mutation of CCRK in mice induces shortened and swollen cilia, which impairs the Hh pathway and leads to a constellation of developmental defects, including exencephaly, cleft palate and mild preaxial polydactyly/limb skeletal defects (39). Immature cilia with ultrastructural malformation are considered to be a true hallmark of glioblastoma tumors and to be associated with their unrestrained growth (40). Yang et al (41) found that the arrested ciliogenesis, and therefore tumor growth, were caused by the elevation of CCRK in glioblastoma. Furthermore, the depletion of CCRK markedly increased the ratio and length of primary cilia in glioblastoma cell lines, and notably, cells with restored cilia exhibited a block or severe delay in cell cycle progression, thus inhibiting tumor cell growth (41). It would be of interest to explore the mechanisms of action of CCRK in primary cilia in glioblastoma in vivo. On the whole, these finding indicate that the suppression of primary ciliogenesis by the upregulation of CCRK may be one of the mechanisms used by glioblastoma cells to provide a growth advantage.

PLK4

PLK4 is a conserved centrosomal protein (CEP) that plays a key role in the centriole duplication cycle in a concentration-dependent manner. The centrioles fail to duplicate when PLK4 malfunctions, while they overamplify when PLK4 is overexpressed (42). However, ciliogenesis is blocked, regardless of its deficiency or overexpression. Although abnormalities in centriole number and structure are commonly observed in cancer, cilia defects caused by PLK4 dysfunction in cancer were not reported until 2014. Shinmura et al (43) reported that the abnormally elevated expression of PLK4 was related to the absence of primary cilia in human gastric cancer. The upregulation of PLK4 mRNA expression was detected in half of the primary gastric cancers. Moreover, an in vitro experiment demonstrated that its overexpression directly caused centrosome amplification, leading to the suppression of ciliogenesis in gastric cancer cell lines (43). Another study overexpressed PLK4 in mice and found that the formation of primary cilia was prevented, cilia signaling was disrupted, and the formation of lymphomas and sarcomas in p53 null mice was advanced (44).

Thymosin β4 (Tβ4)

Tβ4, a 43-amino acid peptide (45), is widely distributed in several cell types, apart from red blood cells, and regulates actin cytoskeleton dynamics by sequestering globular actin monomers (46). Its elevation is highly associated with tumor malignancy in multiple cancer types, including melanoma, head and neck squamous cell carcinoma and bladder cancer (47–49). The cilia ratio is increased by Tβ4 overexpression by upregulating the expression of nephronophthisis 3 (localizing to the basal body and indispensable for cilia integrity) in HeLa human cervical cancer cells (50). Further research by the same research group demonstrated that Tβ4-mediated cilia formation may control HeLa cell growth induced by di-(2-ethylhexyl) phthalate, a xenoestrogen with carcinogenic toxicity (51).

Thus far, the presence of cilia defects in cervical cancer remains contradictable and elusive. Primary cilia were rare in HeLa cells in the study by Alieva et al (52); however, in the study by Kowal and Falk (53), the ciliated population was significantly higher than previously anticipated. In addition, due to the extensive presence of primary cilia, the HeLa cell line was used as a model to explore cilia biology (54). However, these studies only examined primary cilia in the cultured cells and did not set up a strict control group of normal cervical epithelial cells. Therefore, further research is warranted at the tissue level.

Tectonic (TCTN)2

The TCTN family (including TCTN1, TCTN2 and TCTN3) forms complexes with proteins that localize to the transition zone of cilia, where they regulate the composition of the ciliary membrane in a tissue-dependent manner (55). Mutations in TCTNs lead to tissue-specific defects in cilia assembly and trafficking that underlie several ciliopathies (56). However, the available studies on the role of TCTNs in cancer are limited. TCTN1 elevation predicts poor clinical outcomes for patients with glioblastoma (57) and is indispensable for pancreatic cancer cell proliferation (58). Its association with primary cilia in these two cancer types has not yet been investigated, at least to the best of our knowledge. A previous study identified TCTN2 as an oncogene and a tumor marker in several cancer types, including colorectal, lung and ovarian cancer (59). Moreover, inhibiting the expression of TCTN2 has been found to significantly reduce colony formation and cell invasiveness, and impair the assembly of primary cilia in colon cancer cell lines. However, the existing studies are contradictory. Yasar et al (60) observed that the cilia number was elevated in colon adenocarcinoma compared with normal tissues, whereas the study by Rocha et al (61) demonstrated that the cilia number was decreased in colon cancer.

DAB2-interacting protein (DAB2IP)-KIF3a

DAB2IP, a member of the RasGTPase-activating protein family, has been identified as a tumor suppressor in several cancer types (62,63). Its loss is highly prevalent in different subtypes of RCC and is associated with a poor patient survival (64). A recent study found that DAB2IP knockdown impaired primary cilia formation by decreasing the expression of KIF3a (essential for cilia assembly and length maintenance) in kidney epithelial cells (65). In addition, the loss of KIF3a further promotes renal tumorigenesis, suggesting that primary cilia stability is part of the critical homeostatic machinery in renal epithelia (65).

Transforming acidic coiled-coil protein 3 (TACC3)

TACC3, characterized by a highly conserved C-terminal coil domain, is a key component of centrosome-microtubule dynamic networks (66). Recently, TACC3 has been identified as a potential prognostic marker and therapeutic target for various cancer types, such as breast (67) and lung cancer (68). Cilia ratio and length are gradually decreased during the progression from normal prostate to prostatic intraepithelial neoplasia and invasive prostate cancer, and that increase is accompanied by the activation of Wnt signaling (14). However, the mechanisms responsible for cilia defects in prostate cancer remain elusive. A recently published study demonstrated that TACC3 upregulation restrained ciliogenesis in prostate cancer cells (69). TACC3 can competitively bind filamin A and disrupt the michelin-filamin A interaction, which is necessary for centrosome migration to the apical membrane and cilia formation (70). Furthermore, TACC3 knockdown significantly restored the formation of primary cilia and inhibited tumorigenesis and tumor growth in vitro and in vivo, suggesting that targeting TACC3 may represent a novel approach for prostate cancer therapeutics (69).

Molecules regulating cilia disassembly AURKA-HDAC6 signaling axis

As mentioned above, the AURKA-HDAC6 signaling axis plays a critical role in cilia disassembly. AURKA activation is common in multiple cancer types characterized by centrosomal amplification and genomic instability (71,72). The oncogenic AURKA appears to be the key node for the suppression of primary cilia in several types of cancer, including pancreatic ductal adenocarcinoma (PDAC) (73), clear cell RCC (ccRCC) (74), ovarian cancer (75), pheochromocytoma (76) and esophageal squamous cell carcinoma (ESCC) (77). In addition, in a previous study, the number of cilia was significantly decreased in AURKA-activated tissues from patients with OSCC (16). More importantly, AURKA inhibition has been shown to result in primary cilia re-expression and significantly inhibit tumor progression in PDAC, ccRCC and OSCC (16,73,78).

However, the target of AURKA for cilia absorption may vary between tumor types. Unlike ccRCC (74), pheochromocytoma (76) and ESCC (77), cilia loss induced by AURKA activation is independent of HDAC6 in PDAC (73), ovarian cancer (75) and OSCC (16). The specific target of AURKA in these cancer types is unclear. A previous study demonstrated that, in addition to HDAC6, AURKA also activated inositol polyphosphate 5-phosphatase E (INPP5E) (79), a ciliary protein whose absence results in ciliary destabilization and tumor progression in medulloblastoma (80). AURKA may promote cilia loss through INPP5E in PDAC, ovarian cancer and OSCC, which requires further verification.

Gradilone et al (81) focused on the mechanisms of HDAC6 on cilia resorption and cell proliferation in CCA. Their study reported a marked reduction in the number of cilia, which was accompanied by HDAC6 overexpression in clinical CCA tissues. Inhibiting HDAC6 by the pharmacologic inhibitor tubastatin-A or by shRNA could re-express primary cilia in CCA cell lines and decrease cell proliferation. More interestingly, the inhibitory effect of tubastatin-A was abolished after ciliogenesis was blocked by IFT88 knockdown, indicating that the inhibitory effect on cell proliferation through targeting HDAC6 is partially dependent on cilia restoration in CCA cells (81). The latest research from the same research group demonstrated that cilia disassembly in CCA was mediated by HDAC6-regulated autophagy in primary cilia (i.e., ciliophagy), suggesting that ciliophagy inhibition could be an important therapeutic target for CCA (82).

NEK2-KIF24 signaling axis

KIF24, localizing to the distal end of the centriole, depolymerizes the cilia microtubules and provokes cilia disassembly shortly following the stimulation of mitogens (27). The depolymerizing activity of KIF24 is enhanced by NEK2, a kinase only expressed in the S and G2 phases (83). The NEK2-KIF24 action at centriole prevents the aberrant assembly of cilia and keeps the de-ciliated state necessary for mitosis. This mechanism of inhibiting primary ciliogenesis is temporally distinct from the well-established AURKA-HDAC6 pathway by blocking the nucleation of cilia from the basal body (83).

NEK2 has been identified as an oncogene in various cancer types, including myeloma and breast cancer (84–86). Cilia loss is considered to be a characteristic of breast cancer, and the mouse model further confirmed its importance in the development of breast cancer. Although the absence of primary cilia was not found to directly cause breast cancer in mice, it led to the earlier formation and accelerated the growth of cancer, and was associated with a higher grade and metastasis (87). Kim et al (83) found that NEK2-KIF24 was overexpressed in breast cancer cell lines, and their ablation resulted in the re-expression of primary cilia, thereby reducing the proliferation of cancer cells. However, NEK2 has not been reported to induce the loss of primary cilia in other tumors apart from breast cancer.

Tubulin tyrosine ligase like 3 (TTLL3)

The glutamylation of tubulin in mammals can be catalyzed by nine glutamate ligases, in which only two enzymes, TTLL3 and TTLL8, are capable of initiating glycylation on microtubules (88). Glycylation has been found to function as a critical regulator of ciliary disassembly in motile cilia and flagella, while previous studies that used zebrafish or mouse models proved that the integrity of primary cilia was also dependent on this post-translational modification on tubulin (89,90). TTLL3 is the only expressed glycylase in colon tissue, and its knockout in mice has been shown to not only cause a marked reduction in the number of cilia, but to also lead to a markedly increased cell proliferation rate in the colon epithelium. In addition, the lower expression level of TTLL3 has been shown to be significantly associated with the development of colorectal carcinoma, suggesting that cilia defects caused by TTLL3 may serve as a prognostic marker for this type cancer (61).

Molecules playing dual roles in cilia biology Tuberous sclerosis complex (TSC)-mTOR complex 1 (mTORC1) pathway

TSC is a genetic syndrome with widespread dysplastic and multisystemic tumors, caused by the mutations in the tumor suppressor genes, TSC1 and TSC2 (91). TSC1 and TSC2 form a heterodimer that inhibits mTOR signaling by inactivating mTORC1, a type of complex sensitive to rapamycin (92). TSC1, localizing to the basal body (93), is frequently heterozygously lost in ccRCC (94). Activating mTOR signaling by silencing TSC1 lengthened primary cilia in zebrafish (95) and mouse (96) models, and inhibiting mTOR signaling by rapamycin, could return the ciliary length to normal (96). Rosengren et al (97) also found that mTORC1 inhibition by rapamycin resulted in shortened cilia. These studies appear to indicate that mTORC1 plays a positive role in ciliary maintenance. However, another study reported the negative effects of mTORC1 on primary cilia, in which ciliary length was increased following rapamycin treatment in a dose-dependent manner in renal epithelial and vascular endothelial cells (98).

Takahashi et al (99) found that mTORC1 played dual roles in ciliogenesis, since rapamycin treatment shortened the cilia length, whereas it promoted the cilia ratio in retinal pigmented epithelial (RPE1) cells. Furthermore, rapamycin treatment markedly restored the formation of primary cilia and attenuated cell proliferation in lung, kidney, breast and pancreatic cancer cell lines (99). Although the reasons for these discrepancies are unclear, in renal cancer (100) and patients with polycystic kidney disease (101), primary cilia defects are often accompanied by the aberrant activation of mTORC1. In addition, rapamycin and its derivatives have been widely used in the treatment of advanced renal (102) and breast cancer (103).

OFD1 and autophagy

The OFD1 gene was initially identified in OFD syndrome (104) and associated with other ciliopathies, such as Joubert syndrome and retinitis pigmentosa (105). As a component of the distal centriole, OFD1 builds centriole distal appendages, recruits IFT88 and stabilizes centriolar microtubules at a defined length to properly assemble cilia (106). Further research identified that OFD1, similar to CEP290 and pericentriolar material 1, is also the primary component of centriolar satellites, the particles surrounding centrosomes (107). Of note, OFD1 at the centriolar satellites functions as a suppressor of primary cilia, the opposite of the promotion of ciliogenesis observed in distal centrioles. Deficient autophagy-induced OFD1 populated centriolar satellites, leading to fewer and shorter primary cilia and, interestingly, partial OFD1 knockdown significantly restored the cilia formation in MCF7 cells, a human breast cancer cell line that completely lacks primary cilia (108).

The aforementioned study indicated a positive role of autophagy in the regulation of primary cilia formation, while another report recognized basal autophagy as a suppressor in ciliogenesis in primary Hürthle cell tumors. Cilia loss was caused by a high basal autophagic flux, and the inhibition of autophagosome formation notably restored the primary ciliogenesis in tumor cells (109). Pampliega et al (110) also found that autophagy inhibited ciliogenesis and cilia-associated signaling during normal nutritional conditions. On the other hand, Maharjan et al (111) reported that alterations in autophagy during serum-restimulation, irrespective of whether autophagy was activated or inhibited, prevented the disassembly of primary cilia in RPE1 cells. These studies suggest that the regulation of autophagy on primary cilia is likely dependent on the cellular context. Furthermore, the association between primary cilia and autophagy is bidirectional, since the abrogation of ciliogenesis partially inhibits autophagy (110). The regulatory mechanisms between autophagy and primary cilia are further complicated by other cellular events that are usually observed in cancer, such as the activation of AURKA, HDAC6 or other critical factors controlling cilia biology, and thus warrant further investigation (112).

Von Hippel-Lindau (VHL)

VHL has been widely accepted as a component of an E3 ubiquitin ligase that targets hypoxia-inducible factor α for ubiquitination and degradation in an oxygen-dependent manner (113). Its mutation results in VHL disease, the most well-known familial kidney cancer syndrome (114). ccRCC is the most common subtype of renal cancer, and is mainly sporadic. Of note, the VHL gene is inactivated in up to 87% of sporadic ccRCC cases (115). In addition, the re-expression of VHL protein is sufficient to suppress the formation of renal cancer in vivo, suggesting that VHL inactivation is a direct cause of renal tumorigenesis (116).

Primary cilia are almost absent in the renal cysts and ccRCC of patients with VHL (15). In addition, the histological manifestations of early-stage RCC, including increased disorganized cilia, occurred in the kidney of the VHL knockout zebrafish (117). However, in a previous study, ccRCC was not induced by a specific deletion of VHL in mouse renal epithelial cells, suggesting that additional mutations are required in mammals (118). The combined conditional inactivation of VHL and other tumor suppressor factors, Pten or tumor protein p53, gave rise to cilia ablation, renal cysts and neoplastic growth resembling human ccRCC (119,120). Of note, another study detected the mutations of ciliary genes in ~50% of 448 human ccRCC samples, suggesting that the dysfunction of primary cilia plays an important role in at least part of ccRCC (121).

The formation of primary cilia has been shown to be restored by re-expressing the wild-type VHL in VHL-defective ccRCC cell lines (122). However, the mechanisms responsible for cilia defects caused by VHL mutation remain elusive. Schermer et al (116) found that VHL localized on primary cilia and regulated the cilia maintenance by directing the growth of microtubules toward the cell periphery, which is a prerequisite for ciliogenesis. However, a different study revealed that VHL-knockdown led to cilia disassembly by upregulating the expression of NEK8, a cell cycle regulator (123). In addition, VHL knockdown increased AURKA expression by activating β-catenin, thus leading to cilia disassembly. Furthermore, the β-catenin responsive transcription inhibitor rescued cilia defects by inhibiting AURKA, opening new avenues for treatment with β-catenin inhibitors to rescue ciliogenesis in ccRCC (74).

Molecule regulating the transcription of ciliary genes Split ends (Spen)

Spen, characterized by N-terminal RNA-binding motifs, is a large nuclear protein and a component of the HDAC corepressor complex (124). Spen regulates the expression of key transcriptional effectors in multiple signaling pathways (125) and has been established as a tumor suppressor gene by negatively regulating the transcription of estrogen receptor α targets in breast cancer (126). Recently, Spen was found to be co-expressed with the ciliogenic transcription factor, regulatory factor X family member 3. The knockdown of Spen considerably inhibited the formation of primary cilia, and its re-expression rescued ciliogenesis in breast cancer cells (127). Furthermore, the regulation of cell migration by Spen only occurred in those cells harboring primary cilia, indicating that Spen may coordinate cellular movement in a cilia-dependent manner in breast cancer (127).

Enhancer of zeste homolog 2 (EZH2)

EZH2, a histone methyltransferase, is part of polycomb repressive complex 2 (PRC2), which silences target genes epigenetically by catalyzing histone H3 tri-methylation (128). EZH2 is activated in a variety of cancer types and drives cancer progression by suppressing the expression of various tumor suppressor genes (129). Cilia loss is considered to be a promoter and a potential biomarker in melanoma development (10). A recent study (130) reported an inverse correlation between primary cilia and EZH2 expression levels during melanoma development. Activated EZH2 was a driver of melanoma oncogenesis by silencing genes related to ciliary integrity and thus deconstructing primary cilia. Cilia deconstruction further led to the activation of the Wnt/β-catenin pathway, a well-known oncogenic signaling pathway in melanoma. Strikingly, EZH2 activity blockage significantly induced primary ciliogenesis and cilia-dependent tumor growth-arrest, suggesting that rescuing ciliogenesis by targeting EZH2 may serve as a new strategy for melanoma treatment (130).

Syndesmos (SDOS)

SDOS was initially reported to co-localize with syndecan 4 cytoplasmic domain in focal contacts and promotes the assembly of focal adhesions (131). A recent study identified SDOS as a novel RNA-binding protein that interacted with TNF receptor-associated protein 1 at the endoplasmic reticulum to regulate mRNA translation (132). A small subset of mRNAs responsible for the primary ciliogenesis was regulated post-transcriptionally by SDOS, including transmembrane protein 67, coiled-coil and C2 domain containing 2A and Kif7, known as the ciliopathy-associated genes. Furthermore, the regulatory effect of SDOS on primary cilia was further proven in HeLa cells. The number and length of primary cilia were significantly increased in SDOS-silenced HeLa cells, whereas they were decreased in SDOS-overexpressing cells.

Others KRAS proto-oncogene, GTPase (KRAS)

KRAS, having intrinsic GTPase activity, is a small GTP-binding protein and functions as a molecular switch for various cellular processes (133). Its mutation, a common driver in various cancers, locks the protein into the GTP-bound state and results in constitutive signaling, which gives a growth advantage to mutated cells, thereby leading to the development of cancer (134,135). In PDAC, KRAS is the most commonly mutated gene, which is present in >90% of tumor cells (136). In addition, the activation of the oncogenic KRAS allele directly induced the formation of PDAC in mice and blocked ciliogenesis in cancer cells (11). Of note, cilia defects were rescued by inhibiting KRAS effector pathways. The present study raises the possibility that aberrant KRAS signaling may promote carcinogenesis by inducing cilia loss in PDAC.

4. Conclusions and future perspectives

Primary cilia were previously considered as vestigial organelles, while recent advances have recognized the complex biological functions of these unique structures in diseases and cancer. Abnormal signaling pathways lead to uncontrolled proliferation (137), drug resistance (138) and immune escape in cancer (139). As the ‘hub’ for multiple signaling receptors and downstream effector molecules, primary cilia are considered to be the critical regulatory center for inducing pathway defects (140). Primary cilia are likely to impact cancer development in multiple ways, including affecting the cell cycle process (83), mediating signal transduction (141) and regulating the response to therapy targeted to ciliary proteins or related pathways (142). Therefore, several studies have highlighted the possible application of cilia dysfunction in the early diagnosis and prognosis pf cancer.

Primary cilia have been recognized as an important therapeutic target, although the mechanisms of cilia defects are variable in the context of each cancer type (Fig. 3). As already aforementioned, several key factors regulating primary cilia, such as AURKA, HDAC6 and NEK2, have been proven to function as critical oncogenes in the development of various cancer types (13,71,122). Targeting these oncogenic factors and rescuing ciliogenesis can restrain tumor growth, particularly when simultaneously targeting multiple proteins that cause cilia defects. Therefore, targeting these molecules to develop novel therapeutic approaches has been an emerging field in the research of pancreatic, lung, kidney and breast cancer (143).

Although a number of researchers have reported that tumor growth was arrested by re-expressing primary cilia in vivo and in vitro, further extensive research is warranted before targeting cilia can be used in cancer treatment. Firstly, the mechanisms through which primary cilia regulate carcinogenesis differs between cancer types and within cancer subtypes. Secondly, targeting cilia can both restrain tumor progression and induce kinase inhibitor resistance, which appears to prevent achieving good therapeutic effects (142). Primary cilia are complex organelles whose structure, arrangement and function are highly regulated. However, further studies are required to decipher the complex signals they transmit. Nevertheless, existing studies have suggested that the status of primary cilia should play a role in the decision making for precise and personalized treatment.

Acknowledgements

Not applicable.

Availability of data and materials

Not applicable.

Authors' contributions

FY performed the literature search and wrote the manuscript. ZW, CX and FC collected the relevant references and edited the manuscript. QC supervised and revised the manuscript. All authors have read and approved the final manuscript. Data authentication is not applicable.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References 1

Mitchison

Valente

Motile and non-motile cilia in human pathology: From function to phenotypes

J Pathol2412943092017

10.1002/path.4843

27859258

Ansley

Badano

Blacque

Hill

Hoskins

Leitch

Kim

Ross

Eichers

Teslovich

Basal body dysfunction is a likely cause of pleiotropic Bardet-Biedl syndrome

Nature4256286332003

10.1038/nature02030

14520415

Sattar

Gleeson

The ciliopathies in neuronal development: A clinical approach to investigation of Joubert syndrome and Joubert syndrome-related disorders

Dev Med Child Neurol537937982011

10.1111/j.1469-8749.2011.04021.x

21679365

Franco

Thauvin-Robinet

Update on oral-facial-digital syndromes (OFDS)

Cilia5122016

10.1186/s13630-016-0034-4

27141300

Ruiz-Perez

Blair

Rodriguez-Andres

Blanco

Wilson

Liu

Miles

Peters

Goodship

Evc is a positive mediator of Ihh-regulated bone growth that localises at the base of chondrocyte cilia

Development134290329122007

10.1242/dev.007542

17660199

Singla

Reiter

The primary cilium as the cell's antenna: Signaling at a sensory organelle

Science3136296332006

10.1126/science.1124534

16888132

Pala

Alomari

Nauli

Primary cilium-dependent signaling mechanisms

Int J Mol Sci1822722017

10.3390/ijms18112272

29143784

Wong

Seol

Ermilov

Bichakjian

Epstein

JrDlugosz

Reiter

Primary cilia can both mediate and suppress Hedgehog pathway-dependent tumorigenesis

Nat Med15105510612009

10.1038/nm.2011

19701205

Han

Kim

Dlugosz

Ellison

Gilbertson

Alvarez-Buylla

Dual and opposing roles of primary cilia in medulloblastoma development

Nat Med15106210652009

10.1038/nm.2020

19701203

Kim

Dabiri

Seeley

Primary cilium depletion typifies cutaneous melanoma in situ and malignant melanoma

PLoS One6e274102011

10.1371/journal.pone.0027410

22096570

Seeley

Carriere

Goetze

Longnecker

Korc

Pancreatic cancer and precursor pancreatic intraepithelial neoplasia lesions are devoid of primary cilia

Cancer Res694224302009

10.1158/0008-5472.CAN-08-1290

19147554

Menzl

Lebeau

Pandey

Hassounah

Nagle

Weihs

McDermott

Loss of primary cilia occurs early in breast cancer development

Cilia372014

10.1186/2046-2530-3-7

24987519

Mansini

Lorenzo Pisarello

Thelen

Cruz-Reyes

Peixoto

Jin

Howard

Trussoni

Gajdos

LaRusso

MicroRNA (miR)-433 and miR-22 dysregulations induce histone-deacetylase-6 overexpression and ciliary loss in cholangiocarcinoma

Hepatology685615732018

10.1002/hep.29832

29406621

Hassounah

Nagle

Saboda

Roe

Dalkin

McDermott

Primary cilia are lost in preinvasive and invasive prostate cancer

PLoS One8e685212013

10.1371/journal.pone.0068521

23844214

Basten

Willekers

Vermaat

Slaats

Voest

van Diest

Giles

Reduced cilia frequencies in human renal cell carcinomas versus neighboring parenchymal tissue

Cilia222013

10.1186/2046-2530-2-2

23369289

Yin

Chen

Shi

Huang

Qing

Zhong

Xie

Zeng

Activation of EGFR-Aurora A induces loss of primary cilia in oral squamous cell carcinoma

Oral Dis286216302022

10.1111/odi.13791

33529425

Yin

Chen

Shi

Huang

Qing

Zhong

Xie

Zeng

Activation of EGFR-Aurora A induces loss of primary cilia in oral squamous cell carcinoma

Oral Dis286216302022

10.1111/odi.13791

33529425

Hanahan

Weinberg

The hallmarks of cancer

Cell10057702000

10.1016/S0092-8674(00)81683-9

10647931

Sorokin

Centrioles and the formation of rudimentary cilia by fibroblasts and smooth muscle cells

J Cell Biol153633771962

10.1083/jcb.15.2.363

13978319

Sorokin

Reconstructions of centriole formation and ciliogenesis in mammalian lungs

J Cell Sci32072301968

10.1242/jcs.3.2.207

5661997

Reiter

Blacque

Leroux

The base of the cilium: Roles for transition fibres and the transition zone in ciliary formation, maintenance and compartmentalization

EMBO Rep136086182012

10.1038/embor.2012.73

22653444

Bernabe-Rubio

Alonso

Routes and machinery of primary cilium biogenesis

Cell Mol Life Sci74407740952017

10.1007/s00018-017-2570-5

28624967

Sanchez

Dynlacht

Cilium assembly and disassembly

Nat Cell Biol187117172016

10.1038/ncb3370

27350441

Pugacheva

Jablonski

Hartman

Henske

Golemis

HEF1-dependent Aurora A activation induces disassembly of the primary cilium

Cell129135113632007

10.1016/j.cell.2007.04.035

17604723

Inoko

Matsuyama

Goto

Ohmuro-Matsuyama

Hayashi

Enomoto

Ibi

Urano

Yonemura

Kiyono

Trichoplein and Aurora A block aberrant primary cilia assembly in proliferating cells

J Cell Biol1973914052012

10.1083/jcb.201106101

22529102

Kinzel

Boldt

Davis

Burtscher

Trümbach

Diplas

Attié-Bitach

Wurst

Katsanis

Ueffing

Lickert

Pitchfork regulates primary cilia disassembly and left-right asymmetry

Dev Cell1966772010

10.1016/j.devcel.2010.06.005

20643351

Kobayashi

Tsang

Lane

Dynlacht

Centriolar kinesin Kif24 interacts with CP110 to remodel microtubules and regulate ciliogenesis

Cell1459149252011

10.1016/j.cell.2011.04.028

21620453

Miyamoto

Hosoba

Ochiai

Royba

Izumi

Sakuma

Yamamoto

Dynlacht

Matsuura

The Microtubule-depolymerizing activity of a mitotic kinesin protein KIF2A drives primary cilia disassembly coupled with cell proliferation

Cell Rep106646732015

10.1016/j.celrep.2015.01.003

25660017

Kim

Zaghloul

Bubenshchikova

Rankin

Katsanis

Obara

Tsiokas

Nde1-mediated inhibition of ciliogenesis affects cell cycle Re-entry

Nat Cell Biol133513602011

10.1038/ncb2183

21394081

Saito

Chuang

Tseng

Dedesma

Tomizawa

Kaitsuka

Sung

Ciliary transition zone activation of phosphorylated Tctex-1 controls ciliary resorption, S-phase entry and fate of neural progenitors

Nat Cell Biol134024112011

10.1038/ncb2218

21394082

Hanahan

Hallmarks of cancer: New dimensions

Cancer Discov1231462022

10.1158/2159-8290.CD-21-1059

35022204

Nobutani

Shimono

Yoshida

Mizutani

Minami

Kono

Mukohara

Yamasaki

Itoh

Takao

Absence of primary cilia in cell cycle-arrested human breast cancer cells

Genes Cells191411522014

10.1111/gtc.12122

24330390

Yang

Leung

Liu

Eguether

Jun Yao

Jones

Norris

Liu

Clark

INTU is essential for oncogenic Hh signaling through regulating primary cilia formation in basal cell carcinoma

Oncogene36499750052017

10.1038/onc.2017.117

28459465

Frett

Brown

Han

Therapeutic melting pot of never in mitosis gene a related kinase 2 (Nek2): A perspective on Nek2 as an oncology target and recent advancements in Nek2 small molecule inhibition

J Med Chem57583558442014

10.1021/jm401719n

24517277

Yang

Zhang

HDAC6: Physiological function and its selective inhibitors for cancer treatment

Drug Discov Ther72332422013

10.5582/ddt.2013.v7.6.233

24423654

Tam

Wilson

Lefebvre

A CDK-related kinase regulates the length and assembly of flagella in Chlamydomonas

J Cell Biol1768198292007

10.1083/jcb.200610022

17353359

Maurya

Rogers

Sengupta

A CCRK and a MAK kinase modulate cilia branching and length via regulation of axonemal microtubule dynamics in caenorhabditis elegans

Curr Biol2912861300.e42019

10.1016/j.cub.2019.02.062

30955935

Norman

Tran

Fuller

Fukuda

Eggenschwiler

Broad-minded links cell cycle-related kinase to cilia assembly and hedgehog signal transduction

Dev Cell182372472010

10.1016/j.devcel.2009.12.014

20159594

Snouffer

Brown

Lee

Walsh

Lupu

Norman

Lechtreck

Eggenschwiler

Cell Cycle-related kinase (CCRK) regulates ciliogenesis and Hedgehog signaling in mice

PLoS Genet13e10069122017

10.1371/journal.pgen.1006912

28817564

Moser

Fritzler

Rattner

Ultrastructural characterization of primary cilia in pathologically characterized human glioblastoma multiforme (GBM) tumors

BMC Clin Pathol14402014

10.1186/1472-6890-14-40

25228849

Yang

Roine

Makela

CCRK depletion inhibits glioblastoma cell proliferation in a cilium-dependent manner

EMBO Rep147417472013

10.1038/embor.2013.80

23743448

Hori

Barnouin

Snijders

Toda

A non-canonical function of Plk4 in centriolar satellite integrity and ciliogenesis through PCM1 phosphorylation

EMBO Rep173263372016

10.15252/embr.201541432

26755742

Shinmura

Kurabe

Goto

Yamada

Natsume

Konno

Sugimura

PLK4 overexpression and its effect on centrosome regulation and chromosome stability in human gastric cancer

Mol Biol Rep41663566442014

10.1007/s11033-014-3546-2

24981932

Coelho

Bury

Shahbazi

Liakath-Ali

Tate

Wormald

Hindley

Huch

Archer

Skarnes

Over-expression of Plk4 induces centrosome amplification, loss of primary cilia and associated tissue hyperplasia in the mouse

Open Biol51502092015

10.1098/rsob.150209

26701933

Goldstein

Hannappel

Sosne

Kleinman

Thymosin β4: A multi-functional regenerative peptide. Basic properties and clinical applications

Expert Opin Biol Ther1237512012

10.1517/14712598.2012.634793

22074294

Safer

Elzinga

Nachmias

Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable

J Biol Chem266402940321991

10.1016/S0021-9258(20)64278-8

1999398

Cha

Jeong

Kleinman

Role of thymosin beta4 in tumor metastasis and angiogenesis

J Natl Cancer Inst95167416802003

10.1093/jnci/djg100

14625258

Wang

Zhang

Yang

Song

Wei

Gao

Association of thymosin beta4 expression with clinicopathological parameters and clinical outcomes of bladder cancer patients

Neoplasma639919982016

10.4149/neo_2016_619

27596300

Chi

Chang

Chan

Tai

Leung

Chen

Lai

Hsiao

Global Proteomics-based identification and validation of thymosin beta-4 X-Linked as a prognostic marker for head and neck squamous cell carcinoma

Sci Rep790312017

10.1038/s41598-017-09539-w

28831179

Lee

Kim

Moon

Thymosin beta-4 is a novel regulator for primary cilium formation by nephronophthisis 3 in HeLa human cervical cancer cells

Sci Rep968492019

10.1038/s41598-019-43235-1

31048733

Lee

Thuy

Han

Moon

Di-(2-ethylhexyl) phthalate-induced tumor growth is regulated by primary cilium formation via the axis of H₂O₂ production-thymosin beta-4 gene expression

Int J Med Sci18124712582021

10.7150/ijms.53595

33526986

Alieva

Gorgidze

Komarova

Chernobelskaya

Vorobjev

Experimental model for studying the primary cilia in tissue culture cells

Membr Cell Biol128959051999

10512057

Kowal

Falk

Primary cilia found on HeLa and other cancer cells

Cell Biol Int39134113472015

10.1002/cbin.10500

26074404

Vorobyeva

Saunders

Amyloid-beta interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure

Cilia752018

10.1186/s13630-018-0059-y

30140428

Garcia-Gonzalo

Corbit

Sirerol-Piquer

Ramaswami

Otto

Noriega

Seol

Robinson

Bennett

Josifova

A transition zone complex regulates mammalian ciliogenesis and ciliary membrane composition

Nat Genet437767842011

10.1038/ng.891

21725307

Sang

Miller

Corbit

Giles

Brauer

Otto

Baye

Wen

Scales

Kwong

Mapping the NPHP-JBTS-MKS protein network reveals ciliopathy disease genes and pathways

Cell1455135282011

10.1016/j.cell.2011.04.019

21565611

Meng

Chen

Zhao

Wang

Yun

Yang

Chen

Expression and prognostic significance of TCTN1 in human glioblastoma

J Transl Med122882014

10.1186/s12967-014-0288-9

25304031

Zhao

Chen

Wan

Jiang

Cui

Kang

Tectonic 1 is a key regulator of cell proliferation in pancreatic cancer

Cancer Biother Radiopharm317132016

10.1089/cbr.2014.1778

26844847

Cano-Rodriguez

Campagnoli

Grandi

Parri

Camilli

Song

Jin

Lacombe

Pierleoni

Bombaci

TCTN2: A novel tumor marker with oncogenic properties

Oncotarget895256952692017

10.18632/oncotarget.20438

29221125

Yasar

Linton

Slater

Byers

Primary cilia are increased in number and demonstrate structural abnormalities in human cancer

J Clin Pathol705715742017

10.1136/jclinpath-2016-204103

27872140

Rocha

Papon

Cacheux

Marques Sousa

Lascano

Tort

Giordano

Vacher

Lemmers

Mariani

Tubulin glycylases are required for primary cilia, control of cell proliferation and tumor development in colon

EMBO J33224722602014

10.15252/embj.201490279

25180231

Wang

Tseng

Pong

Chen

McConnell

Navone

Hsieh

The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2

J Biol Chem27712622126312002

10.1074/jbc.M110568200

11812785

Shen

Kong

Wan

Wang

Bian

Gan

Wang

Downregulation of DAB2IP results in cell proliferation and invasion and contributes to unfavorable outcomes in bladder cancer

Cancer Sci1057047122014

10.1111/cas.12407

24684735

Wang

Wei

Zhou

Haddad

Zhao

Kapur

Wang

Liao

Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma

Oncotarget731508315192016

10.18632/oncotarget.8971

27129174

Lin

Dang

Hernandez

Hsieh

DAB2IP modulates primary cilia formation associated with renal tumorigenesis

Neoplasia231691802021

10.1016/j.neo.2020.12.002

33341566

Schneider

Essmann

Kletke

Rio

Hanenberg

Wetzel

Schulze-Osthoff

Nürnberg

Piekorz

The transforming acidic coiled coil 3 protein is essential for spindle-dependent chromosome alignment and mitotic survival

J Biol Chem28229273292832007

10.1074/jbc.M704151200

17675670

Campo

Breuer

Inhibition of TACC3 by a small molecule inhibitor in breast cancer

Biochem Biophys Res Commun498108510922018

10.1016/j.bbrc.2018.03.125

29555478

Jiang

Kuang

Que

Lin

Yuan

Xiao

Peng

Zhang

The clinical significance of transforming acidic coiled-coil protein 3 expression in non-small cell lung cancer

Oncol Rep354364462016

10.3892/or.2015.4373

26531241

Qie

Wang

Chen

Ding

Yang

TACC3 promotes prostate cancer cell proliferation and restrains primary cilium formation

Exp Cell Res3901119522020

10.1016/j.yexcr.2020.111952

32156598

Adams

Simms

Abdelhamed

Dawe

Szymanska

Logan

Wheway

Pitt

Gull

Knowles

A meckelin-filamin A interaction mediates ciliogenesis

Hum Mol Genet21127212862012

10.1093/hmg/ddr557

22121117

Goepfert

Adigun

Zhong

Gay

Medina

Brinkley

Centrosome amplification and overexpression of aurora A are early events in rat mammary carcinogenesis

Cancer Res62411541222002

12124350

Gritsko

Coppola

Paciga

Yang

Sun

Shelley

Fiorica

Nicosia

Cheng

Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer

Clin Cancer Res9142014262003

12684414

Kobayashi

Nakazono

Tokuda

Mashima

Dynlacht

Itoh

HDAC2 promotes loss of primary cilia in pancreatic ductal adenocarcinoma

EMBO Rep183343432017

10.15252/embr.201541922

28028031

Dere

Perkins

Bawa-Khalfe

Jonasch

Walker

β-catenin links von Hippel-Lindau to aurora kinase A and loss of primary cilia in renal cell carcinoma

J Am Soc Nephrol265535642015

10.1681/ASN.2013090984

25313256

Egeberg

Lethan

Manguso

Schneider

Awan

Jørgensen

Byskov

Pedersen

Christensen

Primary cilia and aberrant cell signaling in epithelial ovarian cancer

Cilia1152012

10.1186/2046-2530-1-15

23351307

O'Toole

Watson

Novoselova

Romano

LEL

King

Bradshaw

Thompson

Knight

Sharp

Barnes

Oncometabolite induced primary cilia loss in pheochromocytoma

Endocr Relat Cancer261651802019

10.1530/ERC-18-0134

30345732

Chen

Yang

Gong

Liu

Prdx1 promotes the loss of primary cilia in esophageal squamous cell carcinoma

BMC Cancer203722020

10.1186/s12885-020-06898-y

32357862

Wang

Yang

Zhang

Harten

Shukla

Maxwell

Pei

Esteban

VHL inactivation induces HEF1 and Aurora kinase A

J Am Soc Nephrol21204120462010

10.1681/ASN.2010040345

20864688

Plotnikova

Seo

Cottle

Conduit

Hakim

Dyson

Mitchell

Smyth

INPP5E interacts with AURKA, linking phosphoinositide signaling to primary cilium stability

J Cell Sci1283643722015

25395580

Conduit

Ramaswamy

Remke

Watkins

Wainwright

Taylor

Mitchell

Dyson

A compartmentalized phosphoinositide signaling axis at cilia is regulated by INPP5E to maintain cilia and promote Sonic Hedgehog medulloblastoma

Oncogene36596959842017

10.1038/onc.2017.208

28650469

Gradilone

Radtke

Bogert

Huang

Gajdos

LaRusso

HDAC6 inhibition restores ciliary expression and decreases tumor growth

Cancer Res73225922702013

10.1158/0008-5472.CAN-12-2938

23370327

Peixoto

Jin

Thelen

Biswas

Richard

Morleo

Mansini

Holtorf

Carbone

Pastore

HDAC6-dependent ciliophagy is involved in ciliary loss and cholangiocarcinoma growth in human cells and murine models

Am J Physiol Gastrointest Liver Physiol318G1022G10332020

10.1152/ajpgi.00033.2020

32338033

Kim

Lee

Choi

Ringstad

Dynlacht

Nek2 activation of Kif24 ensures cilium disassembly during the cell cycle

Nat Commun680872015

10.1038/ncomms9087

26290419

Cappello

Blaser

Gorrini

Lin

Elia

Wakeham

Haider

Boutros

Mason

Miller

Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells

Oncogene33237523842014

10.1038/onc.2013.183

23708664

Zhou

Yang

Xia

Wang

Salama

Xiong

Shetty

Chen

Zeng

NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers

Cancer Cell2348622013

10.1016/j.ccr.2012.12.001

23328480

Hayward

Clarke

Faragher

Pillai

Hagan

Fry

The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer

Cancer Res64737073762004

10.1158/0008-5472.CAN-04-0960

15492258

Hassounah

Nunez

Fordyce

Roe

Nagle

Bunch

McDermott

Inhibition of ciliogenesis promotes hedgehog signaling, tumorigenesis, and metastasis in breast cancer

Mol Cancer Res15142114302017

10.1158/1541-7786.MCR-17-0034

28611083

Rogowski

Juge

van Dijk

Wloga

Strub

Levilliers

Thomas

Bré

Van Dorsselaer

Gaertig

Janke

Evolutionary divergence of enzymatic mechanisms for posttranslational polyglycylation

Cell137107610872009

10.1016/j.cell.2009.05.020

19524510

Bosch Grau

Masson

Gadadhar

Rocha

Tort

Marques Sousa

Vacher

Bieche

Janke

Alterations in the balance of tubulin glycylation and glutamylation in photoreceptors leads to retinal degeneration

J Cell Sci1309389492017

28104815

Pathak

Austin

Drummond

Tubulin tyrosine ligase-like genes ttll3 and ttll6 maintain zebrafish cilia structure and motility

J Biol Chem28611685116952011

10.1074/jbc.M110.209817

21262966

Curatolo

Bombardieri

Jozwiak

Tuberous sclerosis

Lancet3726576682008

10.1016/S0140-6736(08)61279-9

18722871

Jozwiak

Hamartin and tuberin: Working together for tumour suppression

Int J Cancer118152006

10.1002/ijc.21542

16206276

Hartman

Liu

Zilfou

Robb

Morrison

Watnick

Henske

The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycin-insensitive and polycystin 1-independent pathway

Hum Mol Genet181511632009

10.1093/hmg/ddn325

18845692

Wilson

Bonnet

Guy

Idziaszczyk

Colley

Humphreys

Maynard

Sampson

Cheadle

Tsc1 haploinsufficiency without mammalian target of rapamycin activation is sufficient for renal cyst formation in Tsc1+/- mice

Cancer Res66793479382006

10.1158/0008-5472.CAN-06-1740

16912167

DiBella

Park

Sun

Zebrafish Tsc1 reveals functional interactions between the cilium and the TOR pathway

Hum Mol Genet185956062009

10.1093/hmg/ddn384

19008302

Armour

Carson

Ess

Cystogenesis and elongated primary cilia in Tsc1-deficient distal convoluted tubules

Am J Physiol Renal Physiol303F584F5922012

10.1152/ajprenal.00141.2012

22674026

Rosengren

Larsen

Pedersen

Christensen

Moller

TSC1 and TSC2 regulate cilia length and canonical Hedgehog signaling via different mechanisms

Cell Mol Life Sci75266326802018

10.1007/s00018-018-2761-8

29396625

Sherpa

Atkinson

Ferreira

Nauli

Rapamycin increases length and mechanosensory function of primary cilia in renal epithelial and vascular endothelial cells

Int Educ Res J291972016

28529994

Takahashi

Nagai

Chiba

Nakayama

Mizuno

Glucose deprivation induces primary cilium formation through mTORC1 inactivation

J Cell Sci131jcs2087692018

29180513

100

Huber

Walz

Kuehn

mTOR and rapamycin in the kidney: Signaling and therapeutic implications beyond immunosuppression

Kidney Int795025112011

10.1038/ki.2010.457

21085109

101

Shillingford

Murcia

Larson

Low

Hedgepeth

Brown

Flask

Novick

Goldfarb

Kramer-Zucker

The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease

Proc Natl Acad Sci USA103546654712006

10.1073/pnas.0509694103

16567633

102

Zhang

George

Immunotherapy and targeted-therapy combinations mark a new era of kidney cancer treatment

Nat Med275865882021

10.1038/s41591-021-01320-x

33820997

103

Fan

Sun

Shao

Zhang

Ouyang

Tong

Wang

Luo

Teng

Wang

Effectiveness of adding everolimus to the First-line treatment of advanced breast cancer in premenopausal women who experienced disease progression while receiving selective estrogen receptor modulators: A phase 2 randomized clinical trial

JAMA Oncol7e2134282021

10.1001/jamaoncol.2021.3428

34436536

104

Ferrante

Giorgio

Feather

Bulfone

Wright

Ghiani

Selicorni

Gammaro

Scolari

Woolf

Identification of the gene for oral-facial-digital type I syndrome

Am J Hum Genet685695762001

10.1086/318802

11179005

105

Wang

Chen

Wang

Zhang

Gao

Jin

Tian

OFD1, as a ciliary protein, exhibits neuroprotective function in photoreceptor degeneration models

PLoS One11e01558602016

10.1371/journal.pone.0155860

27196396

106

Singla

Romaguera-Ros

Garcia-Verdugo

Reiter

Ofd1, a human disease gene, regulates the length and distal structure of centrioles

Dev Cell184104242010

10.1016/j.devcel.2009.12.022

20230748

107

Lopes

Prosser

Romio

Hirst

O'Callaghan

Woolf

Fry

Centriolar satellites are assembly points for proteins implicated in human ciliopathies, including oral-facial-digital syndrome 1

J Cell Sci1246006122011

10.1242/jcs.077156

21266464

108

Tang

Lin

Stowe

Chen

Zhu

Stearns

Franco

Zhong

Autophagy promotes primary ciliogenesis by removing OFD1 from centriolar satellites

Nature5022542572013

10.1038/nature12606

24089205

109

Lee

Kang

Chang

Kim

Sul

Kim

Porcelli

Defective ciliogenesis in thyroid hurthle cell tumors is associated with increased autophagy

Oncotarget779117791302016

10.18632/oncotarget.12997

27816963

110

Pampliega

Orhon

Patel

Sridhar

Díaz-Carretero

Beau

Codogno

Satir

Cuervo

Functional interaction between autophagy and ciliogenesis

Nature5021942002013

10.1038/nature12639

24089209

111

Maharjan

Lee

Kwak

Lim

Dutta

Liu

Park

Autophagy alteration prevents primary cilium disassembly in RPE1 cells

Biochem Biophys Res Commun5002422482018

10.1016/j.bbrc.2018.04.051

29649478

112

Lee

Park

Interplay between primary cilia and autophagy and its controversial roles in cancer

Biomol Ther (Seoul)273373412019

10.4062/biomolther.2019.056

31042678

113

Kaelin

JrRatcliffe

Oxygen sensing by metazoans: The central role of the HIF hydroxylase pathway

Mol Cell303934022008

10.1016/j.molcel.2008.04.009

18498744

114

Maher

Kaelin

von Hippel-Lindau disease

Medicine (Baltimore)763813911997

10.1097/00005792-199711000-00001

9413424

115

Arjumand

Sultana

Role of VHL gene mutation in human renal cell carcinoma

Tumour Biol339162012

10.1007/s13277-011-0257-3

22125026

116

Schermer

Ghenoiu

Bartram

Müller

Kotsis

Höhne

Kühn

Rapka

Nitschke

Zentgraf

The von Hippel-Lindau tumor suppressor protein controls ciliogenesis by orienting microtubule growth

J Cell Biol1755475542006

10.1083/jcb.200605092

17101696

117

Noonan

Metelo

Kamei

Peterson

Drummond

Iliopoulos

Loss of vhl in the zebrafish pronephros recapitulates early stages of human clear cell renal cell carcinoma

Dis Model Mech98738842016

10.1242/dmm.024380

27491085

118

Frew

Moch

A clearer view of the molecular complexity of clear cell renal cell carcinoma

Annu Rev Pathol102632892015

10.1146/annurev-pathol-012414-040306

25387056

119

Albers

Rajski

Schonenberger

Harlander

Schraml

von Teichman

Georgiev

Wild

Moch

Krek

Frew

Combined mutation of Vhl and Trp53 causes renal cysts and tumours in mice

EMBO Mol Med59499642013

10.1002/emmm.201202231

23606570

120

Frew

Thoma

Georgiev

Minola

Hitz

Montani

Moch

Krek

pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation

EMBO J27174717572008

10.1038/emboj.2008.96

18497742

121

Harlander

Schonenberger

Toussaint

Prummer

Catalano

Brandt

Moch

Wild

Frew

Combined mutation in Vhl, Trp53 and Rb1 causes clear cell renal cell carcinoma in mice

Nat Med238698772017

10.1038/nm.4343

28553932

122

Esteban

Harten

Tran

Maxwell

Formation of primary cilia in the renal epithelium is regulated by the von Hippel-Lindau tumor suppressor protein

J Am Soc Nephrol17180118062006

10.1681/ASN.2006020181

16775032

123

Ding

Zhou

Liu

Chen

The tumor suppressor pVHL down-regulates never-in-mitosis A-related kinase 8 via hypoxia-inducible factors to maintain cilia in human renal cancer cells

J Biol Chem290138913942015

10.1074/jbc.M114.589226

25451921

124

Oswald

Kostezka

Astrahantseff

Bourteele

Dillinger

Zechner

Ludwig

Wilda

Hameister

Knöchel

SHARP is a novel component of the Notch/RBP-Jkappa signalling pathway

EMBO J21541754262002

10.1093/emboj/cdf549

12374742

125

Ariyoshi

Schwabe

A conserved structural motif reveals the essential transcriptional repression function of Spen proteins and their role in developmental signaling

Genes Dev17190919202003

10.1101/gad.266203

12897056

126

Legare

Cavallone

Mamo

Chabot

Sirois

Magliocco

Klimowicz

Tonin

Buchanan

Keilty

The estrogen receptor cofactor SPEN functions as a tumor suppressor and candidate biomarker of drug responsiveness in hormone-dependent breast cancers

Cancer Res75435143632015

10.1158/0008-5472.CAN-14-3475

26297734

127

Legare

Chabot

Basik

SPEN, a new player in primary cilia formation and cell migration in breast cancer

Breast Cancer Res191042017

10.1186/s13058-017-0897-3

28877752

128

Margueron

Reinberg

The Polycomb complex PRC2 and its mark in life

Nature4693433492011

10.1038/nature09784

21248841

129

Wang

Brea

Immune modulatory functions of EZH2 in the tumor microenvironment: Implications in cancer immunotherapy

Am J Clin Exp Urol785912019

31139703

130

Zingg

Debbache

Peña-Hernández

Antunes

Schaefer

Cheng

Zimmerli

Haeusel

Calçada

Tuncer

EZH2-mediated primary cilium deconstruction drives metastatic melanoma formation

Cancer Cell346984.e142018

10.1016/j.ccell.2018.06.001

30008323

131

Denhez

Wilcox-Adelman

Baciu

Saoncella

Lee

French

Neveu

Goetinck

Syndesmos, a syndecan-4 cytoplasmic domain interactor, binds to the focal adhesion adaptor proteins paxillin and Hic-5

J Biol Chem27712270122742002

10.1074/jbc.M110291200

11805099

132

Avolio

Jarvelin

Mohammed

Agliarulo

Condelli

Zoppoli

Calice

Sarnataro

Bechara

Tartaglia

Protein syndesmos is a novel RNA-binding protein that regulates primary cilia formation

Nucleic Acids Res4612067120862018

30260431

133

Haigis

KRAS alleles: The devil is in the detail

Trends Cancer36866972017

10.1016/j.trecan.2017.08.006

28958387

134

Kempf

Rousseau

Besse

Paz-Ares

KRAS oncogene in lung cancer: Focus on molecularly driven clinical trials

Eur Respir Rev2571762016

10.1183/16000617.0071-2015

26929424

135

Pupo

Avanzato

Middonti

Bussolino

Lanzetti

KRAS-driven metabolic rewiring reveals novel actionable targets in cancer

Front Oncol98482019

10.3389/fonc.2019.00848

31544066

136

Eser

Schnieke

Schneider

Saur

Oncogenic KRAS signalling in pancreatic cancer

Br J Cancer1118178222014

10.1038/bjc.2014.215

24755884

137

Raleigh

Choksi

Krup

Mayer

Santos

Reiter

Hedgehog signaling drives medulloblastoma growth via CDK6

J Clin Invest1281201242018

10.1172/JCI92710

29202464

138

Farooqi

de la Roche

Djamgoz

MBA

Siddik

Overview of the oncogenic signaling pathways in colorectal cancer: Mechanistic insights

Semin Cancer Biol5865792019

10.1016/j.semcancer.2019.01.001

30633978

139

Palicelli

Croci

Bisagni

Zanetti

De Biase

Melli

Sanguedolce

Ragazzi

Zanelli

Chaux

What do we have to know about PD-L1 expression in prostate cancer? a systematic literature review. Part 3: PD-L1, intracellular signaling pathways and tumor microenvironment

Int J Mol Sci22123302021

10.3390/ijms222212297

34830209

140

Eguether

Cordelieres

Pazour

Intraflagellar transport is deeply integrated in hedgehog signaling

Mol Biol Cell29117811892018

10.1091/mbc.E17-10-0600

29540531

141

Deng

Cai

Shi

Jiang

Shang

Wang

Guan

Chen

Rong

Cilia loss sensitizes cells to transformation by activating the mevalonate pathway

J Exp Med2151771952018

10.1084/jem.20170399

29237705

142

Jenks

Vyse

Wong

Kostaras

Keller

Burgoyne

Shoemark

Tsalikis

de la Roche

Michaelis

Primary cilia mediate diverse kinase inhibitor resistance mechanisms in cancer

Cell Rep23304230552018

10.1016/j.celrep.2018.05.016

29874589

143

Khan

Willemarck

Talebi

Marchand

Binda

Dehairs

Rueda-Rincon

Daniels

Bagadi

Thimiri Govinda Raj

Identification of drugs that restore primary cilium expression in cancer cells

Oncotarget7997599922016

10.18632/oncotarget.7198

26862738

Figure 1.

Basic structure of primary cilia. Longitudinal section (left panel) and transverse section (right panel) of primary cilia. The axoneme of primary cilia extends from the basal body, which is anchored to the plasma membrane by transition fibers. Primary cilia contain nine peripheral microtubule pairs and lack a central pair (9+0 pattern), unlike motile cilia (9+2 pattern). Axonemal microtubules are regulated by post-translational modifications. Cargo proteins are transported along the length of the axoneme by IFT, which is powered by kinesin-2 (anterograde transport) or dynein-2 (retrograde transport). IFT, intraflagellar transport; PCM, pericentriolar material; PDGF, platelet-derived growth factor; PTM, post-translational modifications.

Figure 2.

Linkage of primary cilia and centrosomes to the cell cycle. Primary cilia begin to disassemble when cells enter into the cell cycle. The axoneme is depolymerized as cells progress to the S phase, at which centrosomes duplicate and cilia largely disappear. In the early G1 phase, HEF1/AURKA is recruited to the basal body, activating HDAC6. Phosphorylated HDAC6 enters the cilia, de-acetylates microtubules, and leads to axoneme disassembly. At a later point, NEK2 phosphorylating KIF24 and PLK1 phosphorylating KIF2a successively depolymerize the microtubules during the S/G2 and G2/M phases, thereby ensuring that cilia completely disappear. Following mitosis, centrioles are released from the microtubule-organizing center and transform into the basal body again. It is worth noting that only the mother centriole can initiate the assembly process of primary cilia. Narrow gray columns, axonemes; broad grey columns, mother centrioles; purple grey columns, daughter centrioles. AURKA, aurora kinase A; HEF1, human enhancer of filamentation 1; HDAC6, histone deacetylase 6; NEK2, never-in-mitosis-A-related kinase 2; KIF24, kinesin family member 24; PLK1, polo-like kinase 1.

Figure 3.

Overview of molecular targets of cilia defects in different tumor types. This schema was drawn according to the subcellular location of molecules when they regulate the ciliary biology. Further details can be found in the manuscript. CCA, cholangiocarcinoma; ESCC, esophageal squamous cell carcinoma; GBM, glioblastoma; OSCC, oral squamous cell carcinoma; PDAC, pancreatic ductal adenocarcinoma; RCC, renal cell carcinoma; VHL, Von Hippel-Lindau; SDOS, syndesmos; DAB2IP, DAB2-interacting protein; TTLL3, tubulin tyrosine ligase like 3; HDAC6, histone deacetylase 6; INPP5E, inositol polyphosphate 5-phosphatase E; TCTN2, tectonic 2; AURKA, aurora kinase A; NEK2, never-in-mitosis-A-related kinase 2; KIF24, kinesin family member 24; TACC3, transforming acidic coiled-coil protein 3; CCRK, cell cycle-related kinase; SPEN, split ends; EZH2, enhancer of zeste homolog 2.